AdVac

LEAD COVID-19 VACCINE CANDIDATE ANNOUNCED On March 30, 2020 Johnson & Johnson announced a lead vaccine candidate for COVID-19. The COVID-19 vaccine program is leveraging proven technologies from the Janssen Pharmaceutical Companies of Johnson & Johnson. The AdVac® and PER.C6® technologies provide the ability to rapidly develop new vaccine candidates and upscale production of the optimal vaccine candidate. VACCINE CAPABILITIES AND TECHNOLOGIES Our innovative vaccine technology platforms – the AdVac® and PER.C6® technologies – offer real hope for the accelerated development of vaccines and are designed to help the global health community better prepare for and combat life-threatening infectious disease outbreaks. The same technology was used to develop and manufacture the Company's Ebola vaccine and construct our Zika, RSV, and HIV vaccine candidates which are in Phase 2 or Phase 3 clinical development stages. During the Ebola virus epidemic in West Africa, Janssen responded by accelerating Ebola virus vaccine development and scale up, resulting in the manufacturing of more than two million monovalent vaccine regimens in less than one year – utilizing PER.C6®. PER.C6® Technology AdVac® Technology This technology provides a cost-effective manufacturing system for high-yield, faster and large-scale production of vaccines and monoclonal antibodies. It is especially useful for vaccine manufacturing that requires the production of hard-to-grow viruses and could hold the key to making such vaccines affordable for the whole world. A technology based on the development and production of adenovirus vectors (gene carriers). It can be used together with PER.C6® technology to develop recombinant vaccines against life-threatening infec